Emergent BioSolutions Inc. (EBS) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, EBS scores 52 out of 100, earning a D+ grade and the verdict "Roarable Sell — Weak Fundamentals / Trim." The fundamental cash engine pillar scores 13 of 20, with ROIC at 8.9% and FCF yield at 0%, indicating limited cash generation relative to the valuation. Whale 13F flow scores 10 of 20, reflecting institutional accumulation and options positioning that the rating characterizes as weak. Insider conviction scores 13 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 7 of 20, with beta at 1.0 and the rating noting sector sensitivity. Forensic balance sheet scores 9 of 20, with Altman Z at 1.41, Piotroski F at 8 of 9, and Debt/Equity at 1.09.

For a prospective investor, the upside case rests on the low earnings multiple: per the market data, P/E (TTM) is 7 and forward P/E is 6.5, against an EV/EBITDA of 6.6. The downside case rests on weak cash conversion, with the market data showing FCF yield at 0%, and on balance sheet leverage that the forensic pillar flags as a constraint. The rating's verdict frames the risk-adjusted picture as unfavorable at present. This is an educational summary of the rating's components, not personalized advice.

Emergent BioSolutions Inc. is a NYSE-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the company has a market capitalization of $0.4B. Source data does not describe its specific products, customers, or revenue model.

Per the SEC financials, revenue declined from $1049.3M in FY 2023 and $1043.6M in FY 2024 to $742.9M in FY 2025, while operating income turned positive at $100.1M in FY 2025 after prior operating losses. Net margin is 7.1% and operating margin is 13.5% per the market data, with gross margin at 56.1%. Per the Roarable RQD rating, ROIC is 8.9%, Altman Z-Score is 1.41, and Piotroski F-Score is 8 of 9. Debt/Equity is 1.09, and FY 2025 debt of $572.1M compares with cash of $205.4M.

Per the recent news and catalysts feed, the headlines include a GREEN-flagged catalyst item reporting a 14.4% share gain and asking whether further upside remains. A YELLOW market-wire item reports a surge in the stock. A RED RISK WATCH item reports that the CFO, Richard Lindahl, plans to retire and that shares dropped premarket. A YELLOW item reports a director sale of $126k in shares. A second RED RISK WATCH item reports that the stock fell as the CFO plans retirement. The feed contains no proprietary signals per the Butterfly Supply-Chain Graph, which reports no supply chain.

• What specific products, customers, or contracts generate the reported FY 2025 revenue decline from FY 2024?
• What are the terms and maturities of the $572.1M in FY 2025 debt, and what drives the gap between FY 2025 FCF of $156.8M and the 0% FCF yield in the market data?
• What is the reported EPS for each period, given that the financials list EPS as N/A?
• What is the basis for the planned CFO retirement, and what succession arrangements are disclosed?
• What drove the FY 2023 net loss of $-760.5M, and was it recurring or one-time?